New mechanisms in glucose control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic management for the diabetic patient namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also consider other drug classes currently in development and undergoing clinical trials, including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatrics as a management tool for diabetes is covered as well as consideration of the organization of diabetes care with a community focus. ; Index : p.65-66